|

Long-term Follow-up of Depressive Disorders in Psychiatric Care

RECRUITINGSponsored by Region Skane
Actively Recruiting
SponsorRegion Skane
Started2025-06-01
Est. completion2026-12-31
Eligibility
Age18 Years+
Healthy vol.Accepted

Summary

The project investigates long-term prognosis and predictors of treatment outcomes for difficult-to-treat depression in patients in secondary psychiatric care. The current patient cohort was collected in 2012-2021 in the study "Pharmacogenetics in patients with depression with specific focus on difficult-to-treat depression, suicide attempt and CYP2D6". The cohort consists of 415 patients, examined carefully regarding diagnostic assessment and earlier treatment. All participants were also genotyped for the drug metabolizing enzymes CYP2D6 and CYP2C19. Blood samples were stored in biobank for other analyses linked to prognostic markers. The patient cohort will now be followed up with a review of medical records and extraction of register data for a period of 5 years after their participation in the original study. The purpose of the study is to improve treatment and increase knowledge about long-term prognosis in difficult-to-treat depression. This is done by examining symptom profiles, monitoring clinical course and suicidality, and examining prognostic markers.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

Participation in the study "Pharmacogenetics in depressive patients with specific focus on difficult-to-treat depression, suicide attempt and CYP2D6"

Exclusion Criteria:

Not wanting to participate in the follow-up study

Conditions6

AnhedoniaCYP2D6 PolymorphismDepressionPersonality DisordersPsychiatric DiagnosisSuicide, Attempted

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.